Ovarian low malignant potential tumours are unusual growths on the ovaries that sit between benign cysts and true cancer, creating uncertainty but also offering hope for those diagnosed with this condition.

Understanding Prognosis: A Reason for Optimism

When someone receives a diagnosis involving the word “tumor,” fear often takes over immediately. However, ovarian low malignant potential tumours—also called borderline ovarian tumours—offer a remarkably different story from invasive cancers. These growths contain abnormal cells that have characteristics different from completely healthy tissue, but they usually do not behave like aggressive cancers. The outlook for people with this condition is genuinely encouraging, and understanding the numbers can bring much-needed reassurance during a frightening time.^[1]

Statistics paint a hopeful picture. Research following hundreds of patients over many years shows survival rates that far exceed those of invasive ovarian cancer. In one comprehensive review, patients with these tumours had 5-year survival rates of 97%, 10-year rates of 95%, 15-year rates of 92%, and 20-year rates of 89%^[8]. Another large analysis found a 92% survival rate for patients with advanced-stage disease, excluding certain specific complications^[1]. These numbers stand in stark contrast to the approximately 30% survival rate for invasive ovarian cancers^[8].

The stage at diagnosis matters significantly for outcomes. Nearly 75% of borderline tumours are discovered at stage I, meaning the disease remains confined to the ovaries^[8]. For early-stage disease, the outlook is particularly bright—in one series, only 0.7% of patients with stage I tumours died from their disease^[8]. Even when diagnosed at more advanced stages, these tumours behave much less aggressively than true cancers. Patients with stage II disease had a mortality rate of 4.2%, and those with stage III saw 26.8%^[8]—still considerably better than invasive cancer.

Certain factors influence prognosis beyond stage. Younger age at diagnosis, the serous type of borderline tumour (which forms in the cells on the ovary’s surface), and early-stage disease are all associated with better outcomes^[8]. The type of cells found outside the ovaries, if the disease has spread, also matters. When specialists examine tissue removed during surgery, they classify any spread as either invasive or non-invasive implants (deposits of tumour cells in other areas). Non-invasive implants carry a much better prognosis than invasive ones^[8].

Borderline ovarian tumours typically affect younger women, often during their 40s, which is significantly earlier than invasive ovarian cancers^[7]. This younger age at diagnosis means many patients have decades of life ahead, making the excellent long-term survival rates even more meaningful. The disease has not been shown to have a hereditary component like some invasive ovarian cancers do^[7], which may offer some peace of mind to family members concerned about their own risk.

Natural Progression Without Treatment

Understanding how borderline ovarian tumours develop and behave naturally helps explain why they differ so dramatically from invasive cancers. These tumours start in the epithelial tissue—the layer of cells covering the outside of the ovary. Unlike aggressive cancers that rapidly invade surrounding tissues, borderline tumours grow slowly and tend to remain confined to the ovary where they originated^[2].

The cellular changes in borderline tumours represent an in-between state. Under the microscope, pathologists see cells that are abnormal—they don’t look entirely normal, but they also lack the deeply concerning features of invasive cancer cells. These cells have the potential to become cancerous, but in the vast majority of cases, they do not. This biological behaviour explains why the term “borderline” or “low malignant potential” captures their nature—they sit on the border between harmless and harmful^[1].

If left completely untreated, borderline tumours will generally continue growing slowly. The disease usually remains in one ovary, though it’s important to carefully examine the other ovary for signs of disease when one is affected^[1]. In some cases, the tumour may eventually spread beyond the ovary to nearby tissues or, less commonly, to distant areas like the lungs or liver, though this spread happens much less often than with invasive cancers^[2].

The molecular and genetic changes occurring in these tumours suggest they are linked to what scientists call “type I” ovarian tumours, which are low-grade cancers that develop slowly through a step-by-step progression^[12]. Sometimes, a borderline tumour can transform into a low-grade serous carcinoma (a true cancer), but this transformation occurs rarely^[12]. The possibility exists, but it is not the typical path these tumours follow.

One of the distinctive features of borderline tumours is their tendency to recur years after initial treatment. Recurrence can happen as long as 10 to 20 years after surgery, which is why long-term follow-up is essential^[8]. However, when recurrences do occur, they are usually borderline tumours again rather than invasive cancers, and they remain highly treatable with additional surgery. This pattern of recurrence without aggressive transformation further demonstrates why these growths behave so differently from true malignancies.

Possible Complications and Challenges

While borderline ovarian tumours have an excellent overall prognosis, they are not without potential complications. Understanding what can go wrong helps patients and families know what symptoms to watch for and when to seek immediate medical attention.

The location and growth of these tumours can create mechanical problems in the abdomen. As a tumour enlarges, it may press on the bowel, leading to symptoms like bloating, gas, constipation, or changes in bowel habits^[2]. In more serious cases, particularly if the disease has spread within the abdomen, bowel obstruction can occur. This is when the intestine becomes blocked, preventing the normal passage of digestive contents. Bowel obstruction is actually one of the benign complications that, in rare cases, has caused death in patients with borderline tumours—not because of cancer spread, but because of the physical effects of the tumour or scar tissue from previous surgeries^[8].

Ovarian torsion represents another potential complication. This happens when the ovary twists on itself, cutting off its blood supply. Large tumours can increase the risk of torsion, which causes sudden, severe abdominal or pelvic pain and requires emergency surgery to preserve the ovary if caught early enough.

When surgery is performed, like any operation, complications from the procedure itself are possible. These include infection, bleeding, damage to nearby organs like the bladder or bowel, and complications from anesthesia. Blood clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism) can occur after pelvic surgery, though doctors take preventive measures to reduce this risk.

For younger women who undergo fertility-sparing surgery (where the uterus and at least one ovary are preserved), recurrence represents a significant concern. Studies show relapse rates of up to 15% after removal of just the affected ovary, and up to 30% when only the tumour is removed while leaving the ovary intact (cystectomy)^[7]. The good news is that recurrent disease is typically borderline rather than malignant and remains highly curable with additional surgery. However, the need for repeat operations brings its own physical, emotional, and financial burdens.

In rare cases where the tumour spreads beyond the ovaries, the disease can involve the lining of the abdomen (peritoneum), the surface of the liver, or other abdominal organs. When this happens, more extensive surgery may be needed to remove visible disease. Very uncommonly, borderline tumours can spread to distant sites like the lungs or liver, though this occurs much less frequently than with invasive cancers^[2].

The psychological complications of living with a diagnosis that sits in an uncertain territory—not quite benign, not quite cancer—can be profound. The ambiguity can create anxiety that persists long after successful treatment, especially given the possibility of recurrence years or even decades later.

Impact on Daily Life and Coping Strategies

A diagnosis of borderline ovarian tumour affects far more than just physical health. The disease and its treatment ripple through every aspect of a person’s life, from daily activities to relationships, work, and future planning. Understanding these impacts helps patients prepare and develop strategies for maintaining quality of life.

Before treatment, symptoms themselves can disrupt daily life. The abdominal pain, swelling, and bloating that often accompany these tumours can make eating uncomfortable and reduce appetite. Some women feel full quickly after eating only small amounts^[5]. Digestive problems like gas and constipation can be embarrassing and limit social activities. Pelvic pain may interfere with exercise, sexual activity, and even sitting comfortably for extended periods. The need to urinate more frequently can interrupt sleep and make long meetings or travel difficult^[5].

The diagnostic process itself brings stress. Multiple medical appointments, imaging tests, blood draws, and the anxiety of waiting for results can consume significant time and mental energy. Many patients must take time off work for these appointments, creating practical concerns about job security and lost income. The physical examinations required—particularly pelvic exams and transvaginal ultrasounds—can feel invasive and uncomfortable.

Surgery, the primary treatment for borderline tumours, typically requires a recovery period. Most patients need several weeks to heal, during which they cannot lift heavy objects, drive, or return to physically demanding work. The type of surgery significantly impacts recovery. When surgeons can use minimally invasive laparoscopic techniques (small incisions with a camera), recovery is typically faster with less pain and scarring compared to open surgery requiring a larger incision^[5].

For women who undergo removal of both ovaries, especially if they are premenopausal, surgical menopause brings immediate and sometimes severe symptoms. Hot flashes, night sweats, mood changes, vaginal dryness, and sleep disturbances can significantly affect quality of life. Unlike natural menopause, which occurs gradually, surgical menopause happens suddenly, giving the body no time to adjust. This can make symptoms more intense. The long-term health effects of early menopause—including increased risks for osteoporosis and cardiovascular disease—also require management^[5].

Fertility concerns weigh heavily on younger women diagnosed with borderline tumours. These tumours most often affect women in their reproductive years, and many have not completed their families. The choice between more conservative surgery that preserves fertility but carries higher recurrence risk, versus more extensive surgery that better prevents recurrence but ends fertility, creates agonizing decisions. Women who choose fertility-sparing surgery must balance their hopes for future children against the anxiety of potential recurrence. Those who undergo complete removal of reproductive organs must grieve the loss of fertility on top of managing their diagnosis^[7].

Sexual health often suffers. Physical factors like surgical changes, menopausal symptoms (if ovaries are removed), and fatigue combine with emotional factors like anxiety, depression, and altered body image. Pain during intercourse may occur, particularly if surgery has caused scar tissue^[5]. Partners may fear causing pain or harm, affecting intimacy. Open communication with partners and healthcare providers about these issues is crucial, though many women feel too embarrassed to bring them up.

The emotional impact extends to mental health. Anxiety about the uncertain nature of borderline tumours, fear of recurrence, and the stress of medical treatments can trigger or worsen anxiety disorders. Depression is common, particularly when dealing with loss of fertility, surgical menopause, or prolonged medical problems. The need for follow-up appointments every six months can cause “scanxiety”—the anxiety that builds before each surveillance visit, wondering if the tumour has returned^[2].

Practical concerns include financial stress from medical bills, lost work time, and ongoing medical care. Even with insurance, out-of-pocket costs for surgery, medications, and follow-up care can be substantial. Career impacts may extend beyond immediate recovery, especially if recurrence requires additional treatments years later.

Coping strategies that help include maintaining regular follow-up care but trying not to let medical appointments dominate thoughts between visits. Staying physically active within medical restrictions helps both physical and mental health. Building a strong support network of family, friends, and healthcare providers creates a safety net. Some women find journaling, meditation, or mindfulness practices helpful for managing anxiety. Working with a therapist who specializes in chronic illness or cancer-related issues can provide professional support for emotional challenges.

Support for Family and Understanding Clinical Trials

Family members and close friends play a crucial role in supporting someone diagnosed with a borderline ovarian tumour. However, many loved ones feel uncertain about how to help, what to say, or what to expect. Understanding the disease and being aware of clinical trial opportunities can help families provide better support.

The first challenge families often face is understanding what borderline tumours actually are. When they hear the word “tumour,” many assume it means cancer, which can create unnecessary panic. Helping family members understand the significant differences between borderline tumours and invasive cancers—the much better prognosis, the rarity of malignant transformation, and the high cure rates—provides realistic hope and reduces anxiety for everyone involved.

During the diagnostic phase, families can help by accompanying the patient to appointments, taking notes during discussions with doctors, and helping track the multiple tests and results. Medical information can be overwhelming, especially when someone is anxious, and having another person present to remember what was said is invaluable. Families should remember that symptoms like abdominal pain and bloating may seem vague or nonspecific, but they should be taken seriously and prompt medical evaluation^[1].

Regarding clinical trials, families should know that for borderline ovarian tumours, surgery is almost always the only treatment needed^[5]. Unlike many cancers where experimental drugs or therapies are being tested, borderline tumours typically do not require chemotherapy or radiation, so clinical trials for new treatments are less common for this condition. However, research does continue in several important areas.

Clinical trials for borderline tumours might focus on better ways to diagnose these tumours before surgery, improved surgical techniques that preserve fertility while minimizing recurrence risk, or better methods for predicting which patients are at highest risk for recurrence. Some research examines the molecular and genetic characteristics of borderline tumours to better understand their development and identify which tumours might be more likely to progress^[12].

If a borderline tumour does recur and shows signs of transforming into invasive cancer, clinical trials testing new chemotherapy drugs or targeted therapies might become relevant. In rare cases where hormone therapy after surgery is being considered, trials examining the effectiveness of endocrine treatments might be available^[5].

Families can help by researching clinical trial opportunities at major cancer centers. University-affiliated hospitals and National Cancer Institute-designated cancer centers often have the most active research programs. Websites like ClinicalTrials.gov provide searchable databases of ongoing studies. When a loved one has a gynecologic oncology specialist (a surgeon who specializes in female reproductive organ cancers), these doctors typically know about relevant trials and can advise whether participation might be beneficial.

Understanding the purpose of clinical trials helps families support informed decision-making. Trials aim to answer specific research questions and advance medical knowledge that will help future patients. They involve careful monitoring and follow strict safety protocols. However, participation also means additional appointments, possible placebo treatments in some studies, and unknown risks or side effects. The decision to join a trial should balance potential personal benefit against the contribution to medical science.

Beyond clinical trials, families can provide practical support during treatment and recovery. This includes helping with household tasks, childcare, meal preparation, and transportation to appointments. After surgery, patients need someone to drive them home and stay with them initially. Physical tasks like grocery shopping, cleaning, and lifting are often restricted during recovery.

Emotional support matters enormously. Sometimes just listening without trying to fix everything helps most. Avoiding phrases like “at least it’s not cancer” or “you’re lucky it’s just borderline” is important—even though the prognosis is excellent, the patient is still dealing with a serious medical condition, surgery, possible loss of fertility, and significant anxiety. Acknowledging these difficulties while maintaining hope about the good prognosis strikes the right balance.

For women facing fertility decisions, partners and family members should participate in these discussions with healthcare providers. The choice between fertility-sparing surgery with higher recurrence risk versus more definitive surgery affects not just the patient but the entire family’s future. These decisions require careful consideration of family planning goals, the patient’s age, the specific features of the tumour, and personal values.

Long-term, families should understand the need for continued surveillance. Follow-up appointments typically occur every six months to check for recurrence^[2]. This long-term monitoring can last many years or even decades. Supporting consistent attendance at these appointments while helping the patient maintain a normal life between visits requires balance. The goal is vigilance without letting the disease dominate every aspect of life.